BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xiang H, Fox JA, Totpal K, Aikawa M, Dupree K, Sinicropi D, Lowe J, Escandón E. Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors. Oncogene. 2002;21:3611-3619. [PMID: 12032863 DOI: 10.1038/sj.onc.1205449] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Liang X, Du J, Liu Y, Cui M, Ma C, Han L, Qu Z, Zhang Z, Sun Z, Zhang L, Chen YH, Sun W. The hepatitis B virus protein MHBs(t) sensitizes hepatoma cells to TRAIL-induced apoptosis through ERK2. Apoptosis 2007;12:1827-36. [DOI: 10.1007/s10495-007-0114-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
2 Buchsbaum DJ, Zhou T, Lobuglio AF. TRAIL receptor-targeted therapy. Future Oncol 2006;2:493-508. [PMID: 16922616 DOI: 10.2217/14796694.2.4.493] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
3 Chopin V, Toillon RA, Jouy N, Le Bourhis X. P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene. 2004;23:21-29. [PMID: 14712207 DOI: 10.1038/sj.onc.1207020] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 4.0] [Reference Citation Analysis]
4 Ediriwickrema A, Zhou J, Deng Y, Saltzman WM. Multi-layered nanoparticles for combination gene and drug delivery to tumors. Biomaterials 2014;35:9343-54. [PMID: 25112935 DOI: 10.1016/j.biomaterials.2014.07.043] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
5 Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 2003;4:721-9. [PMID: 14662428 DOI: 10.1016/s1470-2045(03)01277-4] [Cited by in Crossref: 361] [Cited by in F6Publishing: 96] [Article Influence: 19.0] [Reference Citation Analysis]
6 Pei XY, Dai Y, Grant S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 2003;17:2036-45. [PMID: 14513055 DOI: 10.1038/sj.leu.2403109] [Cited by in Crossref: 103] [Cited by in F6Publishing: 89] [Article Influence: 5.4] [Reference Citation Analysis]
7 Gajewski TF. On the TRAIL Toward Death Receptor–Based Cancer Therapeutics. JCO 2007;25:1305-7. [DOI: 10.1200/jco.2006.09.9804] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
8 Spierings DC, de Vries EG, Stel AJ, te Rietstap N, Vellenga E, de Jong S. Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. Oncogene 2004;23:4862-72. [PMID: 15122333 DOI: 10.1038/sj.onc.1207617] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
9 Oliver PG, LoBuglio AF, Zinn KR, Kim H, Nan L, Zhou T, Wang W, Buchsbaum DJ. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Clin Cancer Res 2008;14:2180-9. [PMID: 18381960 DOI: 10.1158/1078-0432.CCR-07-1392] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
10 Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008;118:1979-90. [PMID: 18523647 DOI: 10.1172/JCI34359] [Cited by in Crossref: 236] [Cited by in F6Publishing: 118] [Article Influence: 16.9] [Reference Citation Analysis]
11 Stolfi C, Pallone F, Monteleone G. Molecular targets of TRAIL-sensitizing agents in colorectal cancer. Int J Mol Sci 2012;13:7886-901. [PMID: 22942679 DOI: 10.3390/ijms13077886] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
12 Frese S, Pirnia F, Miescher D, Krajewski S, Borner MM, Reed JC, Schmid RA. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene 2003;22:5427-35. [DOI: 10.1038/sj.onc.1206842] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 3.6] [Reference Citation Analysis]
13 Herzer K, Ganten TM, Schulze-Bergkamen H, Grosse-Wilde A, Koschny R, Krammer PH, Walczak H. Transforming growth factor beta can mediate apoptosis via the expression of TRAIL in human hepatoma cells. Hepatology 2005;42:183-92. [PMID: 15962328 DOI: 10.1002/hep.20757] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
14 Van Geelen CM, de Vries EG, de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat 2004;7:345-58. [PMID: 15790545 DOI: 10.1016/j.drup.2004.11.002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 6.6] [Reference Citation Analysis]
15 Schmelz K, Wieder T, Tamm I, Müller A, Essmann F, Geilen CC, Schulze-Osthoff K, Dörken B, Daniel PT. Tumor necrosis factor alpha sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-kappaB. Oncogene 2004;23:6743-59. [PMID: 15273737 DOI: 10.1038/sj.onc.1207848] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
16 Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008;7:1001-12. [DOI: 10.1038/nrd2637] [Cited by in Crossref: 299] [Cited by in F6Publishing: 274] [Article Influence: 21.4] [Reference Citation Analysis]
17 Sano E, Kazaana A, Tadakuma H, Takei T, Yoshimura S, Hanashima Y, Ozawa Y, Yoshino A, Suzuki Y, Ueda T. Interleukin-6 sensitizes TNF-α and TRAIL/Apo2L dependent cell death through upregulation of death receptors in human cancer cells. Biochim Biophys Acta Mol Cell Res 2021;1868:119037. [PMID: 33839168 DOI: 10.1016/j.bbamcr.2021.119037] [Reference Citation Analysis]
18 Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A. TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev 2009;35:280-8. [PMID: 19117685 DOI: 10.1016/j.ctrv.2008.11.006] [Cited by in Crossref: 196] [Cited by in F6Publishing: 180] [Article Influence: 14.0] [Reference Citation Analysis]
19 Bastin-Coyette L, Cardoen S, Smal C, de Viron E, Arts A, Amsailale R, Van Den Neste E, Bontemps F. Nucleoside analogs induce proteasomal down-regulation of p21 in chronic lymphocytic leukemia cell lines. Biochem Pharmacol 2011;81:586-93. [PMID: 21168391 DOI: 10.1016/j.bcp.2010.12.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
20 Kazaana A, Sano E, Yoshimura S, Makita K, Hara H, Yoshino A, Ueda T. Promotion of TRAIL/Apo2L-induced apoptosis by low-dose interferon-β in human malignant melanoma cells. J Cell Physiol 2019;234:13510-24. [PMID: 30613977 DOI: 10.1002/jcp.28029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 Taketani K, Kawauchi J, Tanaka-Okamoto M, Ishizaki H, Tanaka Y, Sakai T, Miyoshi J, Maehara Y, Kitajima S. Key role of ATF3 in p53-dependent DR5 induction upon DNA damage of human colon cancer cells. Oncogene 2012;31:2210-21. [PMID: 21927023 DOI: 10.1038/onc.2011.397] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
22 Edagawa M, Kawauchi J, Hirata M, Goshima H, Inoue M, Okamoto T, Murakami A, Maehara Y, Kitajima S. Role of activating transcription factor 3 (ATF3) in endoplasmic reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through up-regulation of death receptor 5 (DR5) by zerumbone and celecoxib. J Biol Chem 2014;289:21544-61. [PMID: 24939851 DOI: 10.1074/jbc.M114.558890] [Cited by in Crossref: 63] [Cited by in F6Publishing: 40] [Article Influence: 7.9] [Reference Citation Analysis]
23 Lee S, Yagita H, Sayers TJ, Celis E. Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors. Cancer Immunol Immunother 2010;59:1073-81. [PMID: 20213120 DOI: 10.1007/s00262-010-0834-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
24 Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, O'bryant C, Hariharan S, Diab S, Fox NL, Miceli R, Eckhardt SG. Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study. JCO 2009;27:4413-21. [DOI: 10.1200/jco.2008.21.7422] [Cited by in Crossref: 91] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
25 Guichard SM, Hua ML, Kang P, Macpherson JS, Jodrell DI. Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model. Cancer Chemother Pharmacol 2007;60:651-60. [DOI: 10.1007/s00280-006-0408-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
26 Rimondi E, Secchiero P, Quaroni A, Zerbinati C, Capitani S, Zauli G. Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation. J Cell Physiol 2006;206:647-54. [PMID: 16245299 DOI: 10.1002/jcp.20512] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.8] [Reference Citation Analysis]
27 Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 2008;26:3621-3630. [PMID: 18640940 DOI: 10.1200/jco.2007.15.7198] [Cited by in Crossref: 311] [Cited by in F6Publishing: 147] [Article Influence: 22.2] [Reference Citation Analysis]
28 Lakshmikanthan V, Kaddour-Djebbar I, Lewis RW, Kumar MV. SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis. Int J Cancer 2006;119:221-8. [PMID: 16450389 DOI: 10.1002/ijc.21824] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
29 Chen LH, Liu XS, Wang WY, Han WN, Pan BR, Jin BQ. Localization of TRAIL/TRAILR in fetal pancreas. World J Gastroenterol 2003; 9(2): 334-337 [PMID: 12532461 DOI: 10.3748/wjg.v9.i2.334] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
30 Buchsbaum DJ, Forero-Torres A, LoBuglio AF. TRAIL-receptor antibodies as a potential cancer treatment. Future Oncol 2007;3:405-9. [PMID: 17661715 DOI: 10.2217/14796694.3.4.405] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
31 Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate. 2005;62:165-186. [PMID: 15389801 DOI: 10.1002/pros.20126] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 4.8] [Reference Citation Analysis]
32 DeRosier LC, Buchsbaum DJ, Oliver PG, Huang ZQ, Sellers JC, Grizzle WE, Wang W, Zhou T, Zinn KR, Long JW, Vickers SM. Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin Cancer Res 2007;13:5535s-43s. [PMID: 17875786 DOI: 10.1158/1078-0432.CCR-07-1075] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]